T. van der Horst

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

Peter Thuss‐Patience, Manish A. Shah, Atsushi Ohtsu et al. · The Lancet Oncology · 2017 · 522 citations · Full text

Gastrointestinal Oncology, Gastro-oesophageal Junction Adenocarcinoma, Medicine +8

A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC).

Yoon‐Koo Kang, Manish A. Shah, Atsushi Ohtsu et al. · Journal of Clinical Oncology · 2016 · 84 citations

Adaptive Phase 2/3, Breast Oncology, Esophageal Cancer +18

Sustainable Product-Service-Systems: the Kathalys method

Helma Luiten, Marjolijn Knot, T. van der Horst · Proceedings Second International Symposium on Environmentally Conscious Design and Inverse Manufacturing · 2003 · 59 citations

Engineering, Sustainable Development, Sustainable Innovation +21

Malaria infection prevalence and sensitivity of reactive case detection in Zanzibar

Logan Stuck, Bakar S. Fakih, Abdul-wahid Al-mafazy et al. · International Journal of Infectious Diseases · 2020 · 50 citations · Full text

Operational Coverage and Timeliness of Reactive Case Detection for Malaria Elimination in Zanzibar, Tanzania

T. van der Horst, Abdul-wahid Al-mafazy, Bakar S. Fakih et al. · American Journal of Tropical Medicine and Hygiene · 2019 · 32 citations · Full text

Malaria, Private Hfs, Disease Outbreak +20